Sonoma Pharmaceuticals Inc
SNOA3.630USD
+0.050+1.40%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
5.99MMarket Cap
LossP/E TTM
More Details of Sonoma Pharmaceuticals Inc Company
Sonoma Pharmaceuticals, Inc. is a global healthcare company. The Company is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. It offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.
Sonoma Pharmaceuticals Inc Info
Ticker SymbolSNOA
Company nameSonoma Pharmaceuticals Inc
IPO dateJan 26, 2007
CEOTrombly (Amy)
Number of employees168
Security typeOrdinary Share
Fiscal year-endJan 26
Address5445 Conestoga Court, Suite 150
CityBOULDER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code80301
Phone18007599305
Websitehttps://sonomapharma.com/
Ticker SymbolSNOA
IPO dateJan 26, 2007
CEOTrombly (Amy)
Company Executives of Sonoma Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jay E. Birnbaum, Ph.D.
Dr. Jay E. Birnbaum, Ph.D.
Independent Director
Independent Director
286.00
-0.35%
Mr. Jerry G. Mclaughlin
Mr. Jerry G. Mclaughlin
Lead Independent Director
Lead Independent Director
--
--
Mr. Philippe Weigerstorfer
Mr. Philippe Weigerstorfer
Independent Director
Independent Director
--
--
Mr. Jerry Dvonch
Mr. Jerry Dvonch
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Amy Trombly
Ms. Amy Trombly
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jay E. Birnbaum, Ph.D.
Dr. Jay E. Birnbaum, Ph.D.
Independent Director
Independent Director
286.00
-0.35%
Mr. Jerry G. Mclaughlin
Mr. Jerry G. Mclaughlin
Lead Independent Director
Lead Independent Director
--
--
Mr. Philippe Weigerstorfer
Mr. Philippe Weigerstorfer
Independent Director
Independent Director
--
--
Mr. Jerry Dvonch
Mr. Jerry Dvonch
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Amy Trombly
Ms. Amy Trombly
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Human Care
3.56M
88.54%
Animal Care
460.00K
11.46%
By RegionUSD
Name
Revenue
Proportion
Europe
1.47M
36.56%
United States
1.00M
25.03%
Asia
662.00K
16.49%
Latin America
564.00K
14.05%
Rest of the world
316.00K
7.87%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Human Care
3.56M
88.54%
Animal Care
460.00K
11.46%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
1.23%
Geode Capital Management, L.L.C.
1.04%
DRW Securities, LLC
1.00%
Thornton (Bruce)
0.45%
Trombly (Amy Moss)
0.45%
Other
95.83%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
1.23%
Geode Capital Management, L.L.C.
1.04%
DRW Securities, LLC
1.00%
Thornton (Bruce)
0.45%
Trombly (Amy Moss)
0.45%
Other
95.83%
Shareholder Types
Shareholders
Proportion
Investment Advisor
2.31%
Individual Investor
1.24%
Investment Advisor/Hedge Fund
1.04%
Hedge Fund
0.09%
Research Firm
0.05%
Other
95.27%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
34
106.22K
6.24%
+25.12K
2025Q2
39
61.63K
4.65%
-24.83K
2025Q1
40
54.41K
3.31%
-8.75K
2024Q4
40
41.45K
2.57%
-24.32K
2024Q3
41
49.08K
3.40%
+9.77K
2024Q2
40
43.04K
3.61%
+17.90K
2024Q1
38
20.55K
2.85%
-9.28K
2023Q4
36
27.53K
4.02%
+7.17K
2023Q3
35
18.63K
7.25%
-6.00K
2023Q2
37
18.70K
7.42%
+4.13K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
18.79K
1.14%
--
--
Aug 31, 2025
Geode Capital Management, L.L.C.
17.62K
1.07%
+812.00
+4.83%
Jun 30, 2025
Thornton (Bruce)
7.72K
0.47%
-1.00
-0.01%
Jul 08, 2025
Trombly (Amy Moss)
7.68K
0.47%
--
--
Jul 08, 2025
Dvonch (Jerome J)
4.23K
0.26%
-1.00
-0.02%
Jul 08, 2025
Tower Research Capital LLC
1.00K
0.06%
-447.00
-30.89%
Jun 30, 2025
Dal (Poggetto John)
910.00
0.06%
+910.00
--
Jun 20, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 28, 2024
Merger
20→1
Aug 28, 2024
Merger
20→1
Aug 28, 2024
Merger
20→1
Aug 28, 2024
Merger
20→1
Date
Type
Ratio
Aug 28, 2024
Merger
20→1
Aug 28, 2024
Merger
20→1
Aug 28, 2024
Merger
20→1
Aug 28, 2024
Merger
20→1
FAQs
Who are the top five shareholders of Sonoma Pharmaceuticals Inc?
The top five shareholders of Sonoma Pharmaceuticals Inc are:
The Vanguard Group, Inc. holds 18.79K shares, accounting for 1.14% of the total shares.
Geode Capital Management, L.L.C. holds 17.62K shares, accounting for 1.07% of the total shares.
Thornton (Bruce) holds 7.72K shares, accounting for 0.47% of the total shares.
Trombly (Amy Moss) holds 7.68K shares, accounting for 0.47% of the total shares.
Dvonch (Jerome J) holds 4.23K shares, accounting for 0.26% of the total shares.
The Vanguard Group, Inc. holds 18.79K shares, accounting for 1.14% of the total shares.
Geode Capital Management, L.L.C. holds 17.62K shares, accounting for 1.07% of the total shares.
Thornton (Bruce) holds 7.72K shares, accounting for 0.47% of the total shares.
Trombly (Amy Moss) holds 7.68K shares, accounting for 0.47% of the total shares.
Dvonch (Jerome J) holds 4.23K shares, accounting for 0.26% of the total shares.
What are the top three shareholder types of Sonoma Pharmaceuticals Inc?
The top three shareholder types of Sonoma Pharmaceuticals Inc are:
The Vanguard Group, Inc.
Geode Capital Management, L.L.C.
DRW Securities, LLC
The Vanguard Group, Inc.
Geode Capital Management, L.L.C.
DRW Securities, LLC
How many institutions hold shares of Sonoma Pharmaceuticals Inc (SNOA)?
As of 2025Q3, 34 institutions hold shares of Sonoma Pharmaceuticals Inc, with a combined market value of approximately 106.22K, accounting for 6.24% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 1.60%.
What is the biggest source of revenue for Sonoma Pharmaceuticals Inc?
In FY2026Q1, the Human Care business generated the highest revenue for Sonoma Pharmaceuticals Inc, amounting to 3.56M and accounting for 88.54% of total revenue.
